舒洛地特联合瑞格列奈治疗糖尿病肾病的疗效及对血清炎性因子水平的影响  

Efficacy of Sulodexide Combined with Repaglinide in Treatment of Diabetic Nephropathy and Effects on Inflammatory Factors

作　　者：赵宏巧[1] 赵巧飞 焦月江 王彩娥[1] ZHAO Hongqiao;ZHAO Qiaofei;JIAO Yuejiang;WANG Cai＇ e(Dept.of Pharmacy,the First Affiliated Hospital of Henan University of Scienee and Technology,Henan Luoyang 471003,China;Dept.of Gastroenterology,Luoyang Central Hospital Affiliated to Zhengzhou University,Henan Luoyang 471009,China;Dept.of Endocrinology,Luoyang Central Hospital Affiliated to Zhengzhou University,Henan Luoyang 471009,China)

机构地区：[1]河南科技大学第一附属医院药学部,河南洛阳471003 [2]郑州大学附属洛阳中心医院消化科,河南洛阳471009 [3]郑州大学附属洛阳中心医院内分泌科,河南洛阳471009

出　　处：《中国医院用药评价与分析》2018年第7期898-900,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨舒洛地特联合瑞格列奈治疗糖尿病肾病的疗效及对患者血清炎性因子水平的影响。方法:选取2015年12月至2017年12月河南科技大学第一附属医院收治的糖尿病肾病患者100例,按照随机数字表法分为观察组和对照组,每组50例。对照组患者给予瑞格列奈行常规降糖治疗,观察组患者在对照组的基础上加用舒洛地特,疗程均为3个月。比较两组患者的临床疗效及治疗前后24 h尿蛋白量、血清炎性因子水平。结果:观察组患者的总有效率为88.00%(44/50),明显高于对照组的68.00%(34/50),差异有统计学意义(P<0.05)。治疗后,两组患者24 h尿蛋白量均较治疗前明显降低,观察组患者平均24 h尿蛋白量为(1.26±0.45)g,明显低于对照组的(2.15±0.54)g,差异均有统计学意义(P<0.05)。治疗后,两组患者白细胞介素6、肿瘤坏死因子α及超敏C反应蛋白水平较治疗前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。结论:舒洛地特联合瑞格列奈治疗糖尿病肾病的疗效显著,能有效降低患者血清炎性因子水平,改善机体炎症状态。OBJECTIVE： To probe into the efficacy of sulodexide combined with repaglinide in treatment of diabetic nephropathy and effects on inflammatory factors. METHODS： 100 patients with diabetic nephropathy admitted into the First Affiliated Hospital of Henan University of Science and Technology from Dec. 2015 to Dec. 2017 were extracted to be divided into observation group and control group via the random number table,with 50 cases in each. The control group was given regleglin for routine hypoglycemic therapy,while the observation group additionally received sulodexide based on the control group,the treatment course was last for 3 months. The clinical efficacy,changes of 24 h urine protein and serum inflammatory factors before and after treatment of two groups were compared. RESULTS： The total effective rate of observation group was 88. 00%（ 44/50）,significantly higher than that of the control group [68. 00%（ 34/50） ],with statistically significant difference（ P〈0. 05）. After treatment,the 24 h urine protein of two groups decreased significantly compared with before treatment,and the average 24 h urine protein of observation group was（ 1. 26 ± 0. 45） g,significantly lower than that of control group [（ 2. 15 ± 0. 54） g],with statistically significant difference（ P〈0. 05）. After treatment,levels of IL-6,TNF-α and hs-CRP of two groups decreased significantly compared with before treatment,and the observation group was lower than the control group,with statistically significant difference（ P〈0. 05）. CONCLUSIONS： The efficacy of sulodexide combined with repaglinide in treatment of diabetic nephropathy is significant,which can effectively reduce patients＇ inflammatory factors and improve the inflammation.

关 键 词：舒洛地特 瑞格列奈 糖尿病肾病 炎性因子 

分 类 号：R973[医药卫生—药品]